Market Challenges And Opportunities

Rise in burden of chronic diseases to propel market growth

One of the key factors expected to propel growth of the global transfection reagents and equipment market during the forecast period is the rise in burden of chronic diseases worldwide. For instance, such a high burden of chronic diseases leads to an increase in demand for synthetic genes, driving the market growth. Synthetic genes are widely applied in therapy and treat various diseases such as cardiovascular diseases and cancer. As per the World Health Organization (WHO), cancer and cardiovascular diseases (CVDs) are the leading cause of death across the globe, taking an estimated 10 million and 17.9 million lives each year, respectively.

High demand for to transfection reagents and equipment drive market growth

Another factor which is driving growth of the global transfection reagents and equipment market is the increase in demand for transfection reagents and equipment across the globe. For instance, in August 2021, Polypus Transfection SA launched FectoVIR-AAV GMP transfection reagent for large-scale viral vector production to overcome gene and cell therapy manufacturing barriers. The company has also been scaling up of late in order to ensure it can supply transfection reagents to the CGT sector for the next two decades. This in turn is expected to augment growth of the global transfection reagents and equipment market.

Global Transfection Reagents and Equipment Market Opportunities:

Rise in focus on the development of potential in vivo therapies is expected to provide significant growth opportunities for players in the transfection reagents and equipment market. For instance, players in the market are focusing on developing and launching novel potential in vivo therapies in the market to meet growing demand. In July 2020, Polyplus-transfection announced the launch of its GMP-compliant residual test for its PEIpro product portfolio, transfection reagents designed for process development, pre-clinical, clinical, and commercial lentivirus, and Adeno-Associated Virus (AAV) production for cell and gene therapies.

Increase in research and development (R&D) across the globe is expected to offer lucrative growth opportunities for players in the global transfection reagents and equipment market. For instance, in November 2020, Eli Lilly and Company and Precision BioSciences, Inc. announced a research collaboration and exclusive license agreement to use Precision BioScience’ proprietary ARCUS genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne Muscular Dystrophy and two other undisclosed gene targets. This in turn is also expected to boost growth of the market.

Global Transfection Reagents and Equipment Market Restraints:

High cost of transfection reagents to hinder market growth

One of the key factors expected to hinder growth of the global transfection reagents and equipment market is the high cost of transfection reagents. Transfection involves research at the genetic and molecular level, which needs precise and sophisticated reagents. For large-scale applications, the amount of reagent required is considerably high, which in turn increase the cost of the reagent. For instance, the Lipofectamine 3000 transfection reagent (0.75 ml) by ThermoFisher Scientific costs INR 38,559 and the ViaFect Transfection Reagent (0.75 ml) by Promega costs INR 27,975. This in turn is expected to hinder growth of the market.

Limitations of transfection reagents to hamper market growth

Another factor which is hampering the growth of the global transfection reagents and equipment market is the selective effectiveness and certain limitations of transfection reagents. For instance, as the transfection involves the insertion of nucleic acids into the eukaryotic cells, the effectiveness of the certain limitations may hamper the process in reagents or effectiveness of the process. The process’s effectiveness depends highly on the selection of reagents. The selective effectiveness and limitations of reagents significantly affect the results of the process and may restrain growth of the market during the forecast period.